JCIC Asset Management Inc. Sells 73 Shares of Eli Lilly and Company (NYSE:LLY)

JCIC Asset Management Inc. decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 1.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,199 shares of the company’s stock after selling 73 shares during the period. Eli Lilly and Company accounts for about 1.4% of JCIC Asset Management Inc.’s portfolio, making the stock its 25th biggest holding. JCIC Asset Management Inc.’s holdings in Eli Lilly and Company were worth $3,468,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Mascagni Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $43,000. Prudent Man Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $48,000. Highline Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 53.3% in the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company’s stock worth $57,000 after buying an additional 24 shares in the last quarter. Capital A Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $63,000. Finally, Bellwether Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $66,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.8%

Shares of NYSE LLY opened at $792.41 on Thursday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The business’s 50 day moving average price is $782.41 and its 200-day moving average price is $800.16. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The company has a market cap of $751.00 billion, a price-to-earnings ratio of 64.48, a PEG ratio of 1.14 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. During the same quarter in the previous year, the company posted $2.58 earnings per share. The company’s quarterly revenue was up 45.2% compared to the same quarter last year. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.76%. Eli Lilly and Company’s payout ratio is 48.82%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. UBS Group decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. Hsbc Global Res downgraded Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price objective on the stock. Finally, HSBC downgraded Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,011.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.